The present disclosure relates to method of treating or preventing inflammatory bowel disease (IBD) in a subject in need thereof, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs).

Methods and systems and related devices particles and compositions are described for controlled ballistic delivery of particles to a target region of a multilayered tissue, the method comprising determining a velocity v.sub.o,j of the set of substantially spherical particles by iterating v.sub.o,i=√{square root over (Y.sub.a/ρ.sub.p)}((1/k)(d*/D.sup.m)(μ.sub.a.sup.m-1)(√{square root over (Y.sub.aρ.sub.p)}).sup.1-m(ρ.sub.a/ρ.sub.p)).sup.1/n.sup.i from i=0 to j, where n.sub.0=0.826 and n.sub.i=n.sub.0−q(v.sub.0,i-1√{square root over (ρ.sub.a/Y.sub.a)}), until |(v.sub.0,i−v.sub.0,i-1)/v.sub.o,i-1|<0.1; selecting the D.sub.p, ρ.sub.p and v.sub.o,j when v.sub.o,j is less than 1,500 m/sec; and ballistically delivering a set of substantially spherical therapeutic particles having the selected D.sub.p and ρ.sub.p at velocity v.sub.o,j to the accessible surface of the apical layer of the bilayer tissue to deliver into the target region at least 30% of the set of substantially spherical particles.

Disclosed herein are compositions having standardized potencies for use in the treatment of warts. Methods of treating a common wart comprising administering one or more intralesional injections of compositions having standardized potencies to a patient in need thereof are also disclosed. Further disclosed are methods of treating a non-common wart administering one or more intralesional injections of compositions having standardized potencies to a patient in need thereof.

The invention relates to a microbubble-chemotherapeutic agent complex comprising a microbubble carrying a combination of chemotherapeutic agents for use in a method of treating cancer in a patient, wherein said combination of chemotherapeutic agents comprises: (a) a 5-fluoropyrimidine or a derivative thereof; (b) irinotecan or a derivative thereof; and (c) a platinum-based chemotherapeutic agent or a derivative thereof; and wherein said method comprises simultaneous, separate or sequential administration of folinic acid or a derivative thereof. The invention is particularly suitable for use in the treatment of deep-sited tumours and associated metastatic disease, for example in the treatment of pancreatic cancer. The invention further relates to the microbubble- chemotherapeutic agent complexes themselves, to methods for their preparation and to pharmaceutical compositions which contain them, optionally in combination with folinic acid or a folinic acid derivative.

Biopharmaceuticals, such as vaccine agents and probiotics, are encapsulated in carbohydrate-glass particles and embedded in an amorphous polymer substrate to produce polymeric compositions containing ambient-temperature stable biopharmaceuticals for syringeless administration to patients such as via dissolvable films, micro-needle patches and similar medical delivery devices. The amorphous polymer substrate is soluble in both water and a volatile organic solvent, yet the carbohydrate-glass particles are insoluble in the volatile organic solvent.

Exemplary systems and methods associated with trans-tissue substance delivery using non-thermal plasma to porate skin or tissues using contoured dielectrics/electrodes and grounding techniques. In some embodiments, a substance delivery system may be incorporated into the plasma generating device for automatically controlled skin treatments. In other embodiments, a skin treatment patch may include the electrode and the treatment substance.

A method for administering a medicament suitable for treating a migraine or cluster headache to a patient in need thereof includes placing a mounting surface of a fluid delivery apparatus with the medicament in contact with at least a portion of the skin of said patient. A flow rate of the medicament from the fluid delivery apparatus is adjusted such that the medicament is delivered to the patient for at least a predetermined time period. The fluid delivery apparatus includes a controller assembly having a body component defining an axis and a plunger component slidably coupled to the body component. The plunger is positionable between a first position in which the plunger is nearest to the body component and a second position in which the plunger component is furthest from the body component. A bias assembly is positioned between the body component and the plunger component. The bias assembly is configured to apply a two stage force profile to the plunger component. Also disclosed is a method for administering sumatriptan to a patient in need thereof such that the C.sub.max, T.sub.max and AUC are within predetermined, therapeutically effective values.

A transdermal delivery device includes a film having first and second outwardly facing major surfaces; at least one liquid reservoir contained within the film; at least one microfluidic channel having a transverse dimension between about 100 nm and 0.5 mm disposed within the film and in fluid communication with the at least one liquid reservoir; and at least one outlet port associated with at least one microneedle operatively connected to the first outwardly facing major surface of the film in fluid communication with the at least one microfluidic channel.

Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.

The present disclosure relates to nanoparticles, controlled-release dosage forms, and methods for the administration of an immunotherapeutic agent.